Informa

Event Highlights

Preliminary Agenda Highlights

Fast-Track Your Antibody Research to the Clinic and Beyond

ENGINEERING AND APPLICATION OF THERAPEUTIC ANTIBODIES FOR NEURODEGENERATIVE DISEASES

Towards Development of Antibody Therapy for C9orf72 ALS/FTD

Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida


Altering APP Processing with a Proteolytic Diabody

Michael Sierks, Ph.D., Professor, Chemical Engineering, Arizona State University


Tau Immunotherapy

Peter Davies, Feinstein Institute for Medical Research, North Shore/LIJ Health System

PD Immunotherapy - A-Syn

Eliezer Masliah, M.D., Director, Division of Neurosciences, National Institutes of Aging, NIH


Antibody Therapy for Alzheimer's Disease - Key Challenges

Christoph Hock, M.D., Professor and Director, Institute for Regenerative Medicine (IREM), University of Zurich and Co-Founder, Neurimmune, Switzerland

BIOLOGICAL IMPACT OF FC RECEPTOR ENGAGEMENT

SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases

Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan

Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity

James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech


Antibody Optimization for Treg Depletion in Cancer Therapy

Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

Selective FcγR Engagement by Agonistic Anti-CD40 Abs

Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel

Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs

Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

ROLE OF POST-TRANSLATIONAL MODIFICATION IN ANTIBODY FUNCTION

Fc Fucosylation and Sialylation and Antibody Effector Function

Jeffrey Ravetch, Ph.D., Professor, Rockefeller University

Sulfation of Broadly Neutralizing HIV Antibodies

Raiees Andrabi, Research Associate, The Burton Lab,The Scripps Research InstitutePRELIMINARY AGENDA 

Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity

Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, The Netherlands

Post-translational Modification of Antibodies in Rheumatoid Arthritis

Leendert A. Trouw Ph.D., Assistant, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden,The Netherlands

Regulation of Autoantibody Activity by the IL-23-TH17 Axis and its Impact on Autoimmune Disease

Gerhard Kronke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany

IMMUNO-ONCOLOGY: CHECKPOINTS

Development of GARP

Hans de Haard, Ph.D., Chief Scientific Officer, Argenx, Belgium


Megakine: A Novel Receptor Agonist Bispecific Antibody

Cheng-I Wang, Ph.D. Principle Investigator Technologist, Antibodies, Singapore Immunology Network, A*Star, Singapore

ANTIBODY BASED INNOVATIONS IN THE TUMOR MICROENVIRONMENT

Protia - Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment

Volker Schellenberger, Ph.D., CEO and President, Amunix

Immuno-Viral Therapy for Solid Tumors

Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics

Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics

Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members

Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus

mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies

Sebastian Kreiter, Head, Tron/BioNTech, Germany

An Update on the Darzalex Story

Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen

OVERCOMING DELIVERY CHALLENGES INCLUDING BRAIN AND INTRACELLULAR TARGETS

Bacterial Secretion Systems

Thomas Marlovits, Professor, Institute of Molecular Pathology, Austria

Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study

Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium

Bispecific Antibodies Targeting Transfer in Receptor or CD98 to Facilitate Delivery Across the Blood Brain Barrier

Jasi Atwal, Scientist, Genentech

Artificial Immunotoxins

Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, Germany

ANTIBODY-DRUG CONJUGATES & FUSION PROTEINS

Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity

Julian Spallholz, Ph.D., Professor, Nutritional Sciences,Texas Tech University

Antibody-Drug Conjugates for Treating Steroid-Resistant Malignancies and Autoimmune Diseases

Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics,National Cancer Center, Japan

Targeting Tumors and Their Vasculature with Antibody-Drug Conjugates

Dimiter Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH

Novel Calicheamicin Antibody-Drug Conjugates

Julia Gavrilyuk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx

ADDITIONAL SESSIONS

NOVEL ANTIBODY DISPLAY, SELECTION AND SCREENING TECHNOLOGIES

Session Chair: Andrew Bradbury, M.D., Ph.D., Research Scientist and Group Leader,Los Alamos National Laboratories

OVERCOMING TUMOR-BASED RESISTANCE MECHANISMS TO ANTIBODY-INITIATED IMMUNE ATTACK

Session Chair: Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

ROLE OF THE T-CELL REPERTOIRE IN CANCER, INFECTIOUS DISEASES AND AUTOIMMUNITY

Session Chair: Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada

VACCINES AND IMMUNOTHERAPY

Session Chair: Mark Alfenito, Ph.D., President and CEO, EnGen Bio, LLC

ANTI-TUMOR ANTIGEN ANTIBODIES IN CANCER IMMUNOTHERAPY

Session Chair: K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology


* 活动内容有可能不事先告知作更动及调整。